Pussim, What I was saying was that the company
Post# of 15624
(Total Views: 403)
Posted On: 04/18/2018 11:46:38 PM
Pussim,
What I was saying was that the company needs to get the price up before doing the sort of funding necessary to do the full set of trials needed for drug approval for each product. I do believe the FDA is streamlining the process, but it will still be quite costly, especially in Phase 3 or whatever they call it when new FDA guidance comes out.
I believe our share price would be much higher if we just knew things as simple as the protocol for the fibromyalgia trial, which I believe is using fibromyalgia patients in Phase 1, so efficacy could be observed there, but I don't know for a fact that it's the case. If the trial was in the clinical trials database we'd know precisely how it was being done. In fact of all are trials were there, and if they were being routinely updated, we'd know if the start date, end date, etc. were slipping, or if the started on time.
The company wishes to be considered a biotech that happens to work with cannabis. If they acted more like a biotech, those actions alone would move the stock price up dramatically. I'm certain that all the information that goes into the clinical trials database can be found in what is developed with the IRB, it may be in a different format, but I believe all the information and then some is found in the documentation developed prior to the initiation of the trial.
I wouldn't be here if Is didn't believe in the company, but that said, I believe that if they provided the sort of information I'm speaking about the share price would be dramatically higher. Dilution is a fact of life for companies in this status, but clearly if the stock price is higher, you need less of it to raise the same amount. I believe this would be a $2 to $5 share priced stock today if all the trials they're planning were properly documented.
Gary
What I was saying was that the company needs to get the price up before doing the sort of funding necessary to do the full set of trials needed for drug approval for each product. I do believe the FDA is streamlining the process, but it will still be quite costly, especially in Phase 3 or whatever they call it when new FDA guidance comes out.
I believe our share price would be much higher if we just knew things as simple as the protocol for the fibromyalgia trial, which I believe is using fibromyalgia patients in Phase 1, so efficacy could be observed there, but I don't know for a fact that it's the case. If the trial was in the clinical trials database we'd know precisely how it was being done. In fact of all are trials were there, and if they were being routinely updated, we'd know if the start date, end date, etc. were slipping, or if the started on time.
The company wishes to be considered a biotech that happens to work with cannabis. If they acted more like a biotech, those actions alone would move the stock price up dramatically. I'm certain that all the information that goes into the clinical trials database can be found in what is developed with the IRB, it may be in a different format, but I believe all the information and then some is found in the documentation developed prior to the initiation of the trial.
I wouldn't be here if Is didn't believe in the company, but that said, I believe that if they provided the sort of information I'm speaking about the share price would be dramatically higher. Dilution is a fact of life for companies in this status, but clearly if the stock price is higher, you need less of it to raise the same amount. I believe this would be a $2 to $5 share priced stock today if all the trials they're planning were properly documented.
Gary
(4)
(0)